The efficacy of HER2‐targeting NIR‐PIT has also been reported in NSCLC,45 gastric cancer,46 breast cancer,47 bladder cancer,48 and ovarian cancer49 in several preclinical research. Here, ERBB2 is linked to breast carcinoma.